NCT00002130View on ClinicalTrials.gov

A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

NACompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Vesnarinone

Trial Locations (2)

30308

AIDS Research Consortium of Atlanta, Atlanta

900121973

UCLA School of Medicine, Los Angeles

Sponsors
All Listed Sponsors
lead

Otsuka America Pharmaceutical

INDUSTRY

NCT00002130 - A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons | Biotech Hunter | Biotech Hunter